首页> 外文期刊>Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis >Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
【24h】

Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.

机译:单独或在低分子量肝素或普通肝素存在下,通过人纯化抗凝血酶对与人血凝块相关的凝血酶生成的药理调节。

获取原文
获取原文并翻译 | 示例
           

摘要

Procoagulant activities associated with human clots may contribute to thrombus extension. We investigate the inhibition of clot-associated factor Xa and thrombin activities by purified human antithrombin either alone or as combination with a low molecular weight heparin (enoxaparin) as compared with unfractionated heparin (UFH). The standard clots were prepared by recalcification of frozen platelet-poor human plasma. Clot-associated thrombin was measured on the clot after clot incubation in recalcified buffer or recalcified prothrombin solution. The enzymatic reaction was measured using a specific substrate for thrombin (CBS 3447). The thrombin concentration was determined both on the clots and in the reaction mixtures. In parallel, prothrombin fragment 1.2 and thrombin-antithrombin complexes (TAT) were measured using enzyme-linked immunosorbent assay methods. We demonstrated that in the presence of purified human prothrombin and antithrombin (AT), a partial inhibition of clot associated thrombin activity correlated with an increase of TAT complexes. However, antithrombin was unable to inhibit thrombin generation induced by the clot-associated factor Xa. Enoxaparin (low molecular weight heparin) and UFH did not enhance clot-bound thrombin inhibition induced by AT. We conclude that clot-bound thrombin is accessible to human antithrombin alone. AT is also able to inhibit thrombin generated by factor Xa-associated clot. However, neither a low molecular weight heparin or UFH enhanced the effect of AT alone.
机译:与人血凝块有关的促凝血活性可能有助于血栓的扩展。我们研究了与单独的肝素(UFH)相比,纯化的人抗凝血酶单独或与低分子量肝素(依诺肝素)联合使用对凝血相关因子Xa和凝血酶活性的抑制作用。通过重新钙化冷冻的贫血小板人血浆来制备标准血块。在凝块中在重新钙化的缓冲液或重新钙化的凝血酶原溶液中孵育后,测定凝块相关的凝血酶。使用凝血酶的特定底物(CBS 3447)测量酶促反应。测定凝块和反应混合物中的凝血酶浓度。平行地,使用酶联免疫吸附测定法测量凝血酶原片段1.2和凝血酶-抗凝血酶复合物(TAT)。我们证明了在存在纯化的人凝血酶原和抗凝血酶(AT)的情况下,凝块相关凝血酶活性的部分抑制与TAT复合物的增加有关。然而,抗凝血酶不能抑制由凝块相关因子Xa诱导的凝血酶生成。依诺肝素(低分子量肝素)和UFH不能增强AT诱导的凝块结合凝血酶抑制作用。我们得出的结论是,与凝块结合的凝血酶仅对人类抗凝血酶可及。 AT还能够抑制Xa因子相关凝块产生的凝血酶。但是,低分子量肝素或UFH均不能增强AT的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号